STADA Lapatinib 250 mg film-coated tablets (Germany)

Human Epidermal Growth factor receptor 2 positive (HER2+) over expressing advanced or metastatic breast cancer. Lapatinib is indicated in combination with:

• An aromatase inhibitor for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer whose tumours overexpress HER2 (ErbB2) (epidermal growth factor receptor 2) and for whom hormonal therapy is indicated.
• Capecitabine for the treatment of patients with advanced/metastatic breast cancer whose tumours overexpress HER2 (ErbB2) and whose tumours have progressed after treatment with an anthracycline and a taxane, and who have progressed on prior trastuzumab therapy in the metastatic setting.